Study of DCC-2618 in Patients With GIST After at Least 3 Prior Treatments
Recruiting
Phase 1
Interventional Study
Gastrointestinal Stromal Tumors
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 10 (estimated)
- Sponsor
- Ono Pharmaceutical Co., Ltd. · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
To evaluate the safety of DCC-2618 in patients with unresectable, metastatic, or recurrent gastrointestinal stromal tumor (GIST) who have received three or more prior therapies
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Participants with a histologically confirmed diagnosis of GIST.
2. Participants who are refractory or intolerant to treatment with at least imatinib, sunitinib, and regorafenib.
3. Participants with at least one measurable lesion per the modified Response Evaluation Criteria …
Contacts
North America Clinical Trial Support Desk
+18665877745 (Toll-Free)
CONTACT
International Clinical Trial Support Desk
+17162141777 (Standard)
CONTACT